Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours.
about
Cytotoxic and targeted therapy for hereditary cancersTrial watch - inhibiting PARP enzymes for anticancer therapyDNA repair targeted therapy: The past or future of cancer treatment?Olaparib in the management of ovarian cancerPARP inhibitors in the management of breast cancer: current data and future prospectsPARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directionsA Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187.Positive effects on hematological and biochemical imbalances in patients with metastatic breast cancer stage IV, of BP-C1, a new anticancer substanceNivolumab and Olaparib.PARP Inhibitor PJ34 Suppresses Osteogenic Differentiation in Mouse Mesenchymal Stem Cells by Modulating BMP-2 Signaling PathwaySynergetic Effects of PARP Inhibitor AZD2281 and Cisplatin in Oral Squamous Cell Carcinoma in Vitro and in VivoHereditary cancer syndromes: utilizing DNA repair deficiency as therapeutic targetDOXIL when combined with Withaferin A (WFA) targets ALDH1 positive cancer stem cells in ovarian cancerOlaparib: first global approval.Safety evaluation of olaparib for treating ovarian cancer.An overview of tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women's cancers.New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes PTEN/TP53-Deficient Prostate Cancer to Radiation.PARP inhibitors as antitumor agents: a patent update (2013-2015).miR-193b Modulates Resistance to Doxorubicin in Human Breast Cancer Cells by Downregulating MCL-1.PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer.Poly(ADP-ribose)polymerases inhibitors prevent early mitochondrial fragmentation and hepatocyte cell death induced by H2O2.The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells.The development of PARP as a successful target for cancer therapy.Genetic testing in women with breast cancer: implications for treatment.The rise of genomic profiling in ovarian cancer.A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia.An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib.Topoisomerase II Poisons for Glioblastoma; Existing Challenges and Opportunities to Personalize Therapy.Advances in the use of PARP inhibitor therapy for breast cancerBRCA1/2 testing: therapeutic implications for breast cancer management
P2860
Q26739366-42DC29B4-259D-450B-8720-AE3F8C1F40F6Q26745673-B861F33D-E40E-4250-AE77-2968FEC6B56CQ26768679-D7358194-CD89-4B9A-8D56-8D781F350AD9Q26797166-4F0067C5-7CA2-4B8B-9DE5-9E96131BD30AQ26798352-50865B6E-2F30-4548-97C9-B41F1A71C0DEQ28071345-239839B2-2A33-45D4-8BB1-EBFB75CD77FEQ33431474-DCFD641B-DFBA-4244-8574-925D623AFFAAQ35191247-7B63DB8B-DBF4-43FA-8E97-A3672850D649Q36052253-4A9320BB-CD4D-4136-9F0E-FEEB68D36CF7Q36247467-C7164C4F-2272-4F54-BC91-D0E7E8C3BFACQ36743450-DA0214C5-3DA2-4F96-8126-7BB70FD5AEADQ36990060-D580C822-2997-4848-B6F1-2D2CDD02B6B1Q37276254-A0ECA2B7-4BF8-4C1D-936C-44314C8B1154Q38330356-0E4B0F80-AACB-44BA-BF4B-8C5E4E2E5A75Q38519719-17B22DA5-711C-4892-9CD2-EA1328A8E3E2Q38631373-5C79F54D-DB25-4041-B529-5B58FAAB28FDQ38747272-A5FA8153-8878-4FC2-8DEF-2114425F2123Q38756892-9E8BF188-D31E-4CBD-A307-25EF3B629BE8Q38788554-70F72095-A9D8-4818-A57A-F9E36325988FQ38795712-C3A15336-FC20-4598-BADE-C59B824177ACQ41998563-35FCF100-3105-41FC-A54F-DB359D4020B9Q42517340-31D779F0-659B-4E7C-8E07-6B390B4D4D66Q44948950-C47428A2-9034-49B9-B1B4-511B2E0BF00CQ46386898-727366B4-C67A-4673-B29C-B6F018F2EE86Q47278103-C3C2A96E-1676-48CF-810B-A10295C3BC03Q47884776-F21D7CF6-4555-4E69-AE0D-6B957CCCE64CQ50345037-EF25B541-456F-435E-864D-726EC1C80242Q52764412-C701F08F-E601-48A7-935A-B074907D2417Q54011326-2889D65D-AD14-41BA-A578-085711EB9F7FQ55512580-14D51016-FCD2-4990-B7A5-9864B884FE3FQ57108063-209675D7-056C-4B5E-9640-BD123D7B06A5Q57110101-0E3A2AB7-2C01-480D-95DB-A5B0F5479F10
P2860
Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Phase I study of olaparib in c ...... s with advanced solid tumours.
@ast
Phase I study of olaparib in c ...... s with advanced solid tumours.
@en
type
label
Phase I study of olaparib in c ...... s with advanced solid tumours.
@ast
Phase I study of olaparib in c ...... s with advanced solid tumours.
@en
prefLabel
Phase I study of olaparib in c ...... s with advanced solid tumours.
@ast
Phase I study of olaparib in c ...... s with advanced solid tumours.
@en
P2093
P2860
P356
P1476
Phase I study of olaparib in c ...... s with advanced solid tumours.
@en
P2093
A Locatelli
E Gallerani
G Del Conte
R Cathomas
R von Moos
P2860
P2888
P304
P356
10.1038/BJC.2014.345
P407
P577
2014-07-15T00:00:00Z
P5875
P6179
1050827302